Isatuximab, a novel anti-CD38 monoclonal antibody in the treatment of multiple myeloma: efficacy and safety
The article discusses the place of CD38 antibodies in the treatment of multiple myeloma (MM). Special emphasis is put of isatuximab. In 2020, isatuximab in combination with pomalidomide and dexamethasone was approved in Russia for the treatment of adult patients with MM who have received at least tw...
Guardado en:
Autores principales: | Karina E. Zatolochina, Sergey K. Zyryanov, Elena A. Ushkalova |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
IP Habib O.N.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/25784a31084f4d508ceb6bc0d0ac9915 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
New developments in the treatment of multiple myeloma – clinical utility of daratumumab
por: McEllistrim C, et al.
Publicado: (2017) -
A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma
por: Elodie Duray, et al.
Publicado: (2021) -
Structural and functional comparability study of anti-CD20 monoclonal antibody with reference product
por: Singh SK, et al.
Publicado: (2018) -
Role of CD38 in Adipose Tissue: Tuning Coenzyme Availability?
por: Andrea Benzi, et al.
Publicado: (2021) -
Macroglossia reveals multiple myeloma
por: Maria Bonvicini, et al.
Publicado: (2021)